Where does Newron Pharmaceuticals S.p.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Newron Pharmaceuticals S.p.A. ranks #21,510 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Newron Pharmaceuticals S.p.A. hold?

Newron Pharmaceuticals S.p.A. holds 13 US utility patents granted between 2015 and 2025, spanning 5 technology areas.

What is Newron Pharmaceuticals S.p.A.'s Innovation Score?

Newron Pharmaceuticals S.p.A. has an Innovation Score of 32.0 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Newron Pharmaceuticals S.p.A. focus on?

Newron Pharmaceuticals S.p.A.'s top technology area is C07C (Acyclic OR Carbocyclic Compounds) with 12 patents, ranking #377 of 2,691 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Newron Pharmaceuticals S.p.A.'s patent grant rate increasing or decreasing?

Newron Pharmaceuticals S.p.A.'s recent grant velocity is -91% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Newron Pharmaceuticals S.p.A.'s patents?

Newron Pharmaceuticals S.p.A.'s patents average 13.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Newron Pharmaceuticals S.p.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Newron Pharmaceuticals S.p.A.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Newron ranks #21,510 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#21,510
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.0/100): 13.9
avg claims per patent: -91%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R21510 · Foreign Corporation #21,510 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #21,510/49,997
PHOTO-FINISH Nerdbugs
CPC-NARROW C07C · 5 areas
INNOV-THIN 32.0/100
CLAIMS-RICH 13.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -91% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nerdbugs LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Newron’s 32.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (28%) Velocity 6.7 pts (21%) Breadth 7.9 pts (25%) Claim depth 8.4 pts (26%)

Qualcomm Incorporated · highest

85
Newron Pharmaceutica… · this assignee

32
3D Lighting… · lowest

7

What this shows Newron's Innovation Score is 32.0/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Newron?

Each dot is one of Newron’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Newron’s own 13.9 claims/patent is ABOVE the 4.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Newron vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Newron's grants concentrate

Newron Pharmaceuticals S.p.A. is a focused PatentsView assignee: 5 CPC subclasses with 92.3% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2016 (7 grants) versus a trough of 1 in 2015. By volume, Newron sits between Nerdbugs LLC and Ningbo Weitao Electrical Appliance Co., Ltd..

Newron's three-year grant acceleration

Newron Pharmaceuticals S.p.A. shows 1 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nerdbugs

13
Netmarble

13
Nevados Engineeri…

13
New York Universi…

13
Nextier Completio…

13
Ningbo Eudemon Ch…

13
Ningbo Iclipper E…

13
Ningbo Weitao Ele…

13
Newron Pharmaceut… ◀

13

What this shows Newron holds 13 patents at rank #21,529, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Newron

By rank, the assignees closest to #21,529 in granted patent volume.

Leaders in C07C (Acyclic OR Carbocyclic Compounds)

Other assignees with the most granted patents in Newron's primary technology class.

Newron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Newron Pharmaceuticals S.p.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	7.7%
2016	7	53.8%
2017	2	15.4%
2018	1	7.7%
2024	1	7.7%
2025partial year	1	7.7%

Which technologies does Newron Pharmaceuticals S.p.A. patent most?

C07C - Acyclic OR Carbocyclic Compounds 12

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 11

C07D - Heterocyclic Compounds 8

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Newron Pharmaceuticals S.p.A.'s patent record in context - here's where to go next.

Newron Pharmaceuticals S.p.A.'s lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 92.3% of its portfolio - see every assignee active in that class. Explore C07C
Ranked #21,510 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Newron Pharmaceuticals S.p.A. against Nerdbugs LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.